Company Description
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures...
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.
Valuation
P/E Current
64.06
P/E Ratio (with extraordinary items)
85.79
P/E Ratio (without extraordinary items)
45.42
Price to Sales Ratio
14.09
Price to Book Ratio
7.35
Price to Cash Flow Ratio
50.70
Enterprise Value to EBITDA
43.76
Enterprise Value to Sales
14.31
Total Debt to Enterprise Value
0.04
Efficiency
Revenue/Employee
321,170.00
Income Per Employee
99,597.00
Receivables Turnover
5.68
Total Asset Turnover
0.36
Liquidity
Current Ratio
4.88
Quick Ratio
3.92
Cash Ratio
2.54
Profitability
Gross Margin
61.81
Operating Margin
21.26
Pretax Margin
37.43
Net Margin
31.01
Return on Assets
11.31
Return on Equity
17.99
Return on Total Capital
9.01
Return on Invested Capital
13.28
Capital Structure
Total Debt to Total Equity
31.39
Total Debt to Total Capital
23.89
Total Debt to Total Assets
20.63
Long-Term Debt to Equity
29.79
Long-Term Debt to Total Capital
22.68
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Charles R. Kummeth | 58 | 2013 | President, Chief Executive Officer & Director |
Mr. James T. Hippel | 48 | 2014 | CFO & Principal Accounting Officer |
Dr. Robert Monroe | - | 2018 | Chief Medical Officer |
Mr. Kim Kelderman | - | 2018 | President-Diagnostics & Genomics |
Ms. Brenda Swierenga Furlow | 61 | 2014 | Secretary, Senior Vice President & General Counsel |
Insider Actions
02/16/2021 |
Charles R. Kummeth Chief Executive Officer; Director |
17,428 | Derivative/Non-derivative trans. at $411 per share. | 7,162,908 |
02/16/2021 |
Charles R. Kummeth Chief Executive Officer; Director |
30,000 | Derivative/Non-derivative trans. at $94.35 per share. | 2,830,500 |
02/12/2021 |
James T. Hippel Chief Financial Officer |
600 | Disposition at $401.52 per share. | 240,912 |
02/12/2021 |
James T. Hippel Chief Financial Officer |
9,400 | Disposition at $400.32 per share. | 3,763,008 |
02/12/2021 |
Brenda Swierenga Furlow SVP - General Counsel |
3,326 | Disposition at $399.12 per share. | 1,327,473 |
02/12/2021 |
Brenda Swierenga Furlow SVP - General Counsel |
6,674 | Disposition at $398.4 per share. | 2,658,921 |
02/12/2021 |
James T. Hippel Chief Financial Officer |
10,000 | Derivative/Non-derivative trans. at $106.59 per share. | 1,065,900 |
02/12/2021 |
Brenda Swierenga Furlow SVP - General Counsel |
10,000 | Derivative/Non-derivative trans. at $106.59 per share. | 1,065,900 |
02/08/2021 |
Roeland Nusse Director |
6,000 | Disposition at $385.08 per share. | 2,310,480 |
02/08/2021 |
Roeland Nusse Director |
5,000 | Derivative/Non-derivative trans. at $66.9 per share. | 334,500 |
02/08/2021 |
Roeland Nusse Director |
1,000 | Derivative/Non-derivative trans. at $70.35 per share. | 70,350 |
02/05/2021 |
Norman David Eansor President-Protein Sciences |
1,100 | Disposition at $385.59 per share. | 424,149 |
02/05/2021 |
Norman David Eansor President-Protein Sciences |
1,900 | Disposition at $384.15 per share. | 729,885 |
02/05/2021 |
Norman David Eansor President-Protein Sciences |
3,700 | Disposition at $382.6 per share. | 1,415,620 |
02/05/2021 |
Norman David Eansor President-Protein Sciences |
2,900 | Disposition at $381.52 per share. | 1,106,408 |
02/05/2021 |
Norman David Eansor President-Protein Sciences |
12,833 | Disposition at $380.5 per share. | 4,882,956 |
02/05/2021 |
Norman David Eansor President-Protein Sciences |
4,500 | Disposition at $379.62 per share. | 1,708,290 |
02/05/2021 |
Norman David Eansor President-Protein Sciences |
6,000 | Disposition at $378.29 per share. | 2,269,740 |
02/05/2021 |
Kim Kelderman Pres. Diagnostics & Genom |
823 | Disposition at $388.45 per share. | 319,694 |
02/05/2021 |
Norman David Eansor President-Protein Sciences |
18,819 | Derivative/Non-derivative trans. at $106.59 per share. | 2,005,917 |
02/05/2021 |
Norman David Eansor President-Protein Sciences |
14,114 | Derivative/Non-derivative trans. at $106.59 per share. | 1,504,411 |
01/15/2021 |
Charles R. Kummeth Chief Executive Officer; Director |
20,000 | Disposition at $344 per share. | 6,880,000 |
01/11/2021 |
James T. Hippel Chief Financial Officer |
2,009 | Disposition at $334.98 per share. | 672,974 |
01/11/2021 |
James T. Hippel Chief Financial Officer |
3,990 | Disposition at $334.39 per share. | 1,334,216 |
01/11/2021 |
James T. Hippel Chief Financial Officer |
2,501 | Disposition at $333.23 per share. | 833,408 |
01/11/2021 |
James T. Hippel Chief Financial Officer |
700 | Disposition at $331.61 per share. | 232,127 |
01/11/2021 |
James T. Hippel Chief Financial Officer |
400 | Disposition at $330.26 per share. | 132,104 |
01/11/2021 |
James T. Hippel Chief Financial Officer |
400 | Disposition at $328.68 per share. | 131,472 |
01/11/2021 |
James T. Hippel Chief Financial Officer |
10,000 | Derivative/Non-derivative trans. at $106.59 per share. | 1,065,900 |
12/07/2020 |
Charles R. Kummeth Chief Executive Officer; Director |
5,000 | Disposition at $308 per share. | 1,540,000 |
11/30/2020 |
Brenda Swierenga Furlow SVP - General Counsel |
707 | Disposition at $302.82 per share. | 214,093 |
11/30/2020 |
Brenda Swierenga Furlow SVP - General Counsel |
6,783 | Disposition at $302.15 per share. | 2,049,483 |
11/30/2020 |
Brenda Swierenga Furlow SVP - General Counsel |
3,367 | Disposition at $301.32 per share. | 1,014,544 |
11/30/2020 |
Brenda Swierenga Furlow SVP - General Counsel |
938 | Derivative/Non-derivative trans. at $106.59 per share. | 99,981 |
11/30/2020 |
Brenda Swierenga Furlow SVP - General Counsel |
10,857 | Derivative/Non-derivative trans. at $106.59 per share. | 1,157,247 |
11/18/2020 |
Robert V. Baumgartner Director |
5,000 | Disposition at $303.34 per share. | 1,516,700 |
11/18/2020 |
Robert V. Baumgartner Director |
5,000 | Derivative/Non-derivative trans. at $66.9 per share. | 334,500 |
11/11/2020 |
James T. Hippel Chief Financial Officer |
1,100 | Disposition at $307.78 per share. | 338,558 |
11/11/2020 |
James T. Hippel Chief Financial Officer |
6,291 | Disposition at $306.93 per share. | 1,930,896 |
11/11/2020 |
James T. Hippel Chief Financial Officer |
7,391 | Derivative/Non-derivative trans. at $106.59 per share. | 787,806 |
MarketWatch News on TECH
-
Bio-Techne upgraded to buy from hold at Stifel Nicolaus
- Tomi Kilgore
-
Bio-Techne stock price target raised to $400 from $310 at Stifel Nicolaus
- Tomi Kilgore
-
Bio-Techne started at sector weight with $340 stock fair value estimate at KeyBanc Capital
- Tomi Kilgore
-
Bio-Techne downgraded to hold from buy at Stifel Nicolaus
- Tomi Kilgore
-
Bio-Techne started at buy with $290 stock price target at Benchmark
- Tomi Kilgore
-
The Investment Allure of American Water Works
- Barron's Online
-
How to profit from the ‘best of both worlds’ in stock investing
- Philip van Doorn
-
The Best Mutual Funds You’ve Never Heard Of
- Barron's Online
-
This stock picker continues to outperform by using volatility as a ‘friend’
- Philip van Doorn
-
Five Ways to Play a Growing Health Sector
- Barron's Online
-
Bio-Techne stock value estimate raised to $180 from $148 at Janney
- Tomi Kilgore
-
These two trends will continue to power small-cap stocks
- Philip van Doorn
-
3 Growth Stocks for the Long Haul
- Barron's Online
-
What Happened In Pharma Last Quarter?
- Barrons Blogs
-
Bio-Techne downgraded to neutral from buy at Janney
- Tomi Kilgore
-
Bio-Techne started at buy with $115 stock price target at Deutsche Bank
- Tomi Kilgore
-
Tech Data expects deal to add to adjusted EPS in the first year after closing
- Tomi Kilgore
- Loading more headlines...
Other News on TECH
-
Stifel upgrades Bio-Techne to buy from hold, boosts price target
- Seeking Alpha
-
Bio-Techne signs a license agreement with Luminary Therapeutics
- Seeking Alpha
-
Tracking Ron Baron's BAMCO Portfolio - Q4 2020 Update
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Bio-Techne FQ2 2021 Earnings Preview
- Seeking Alpha
-
Tracking Ron Baron's BAMCO Portfolio - Q3 2020 Update
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Bio-Techne Q1 2021 Earnings Preview
- Seeking Alpha
-
Notable earnings before Thursday's open
- Seeking Alpha
-
Abcam Seeks U.S. Investment For Growth Focus
- Seeking Alpha
-
5 Tips for Making Money in Penny Stocks
- InvestorPlace.com
-
Bio-Techne opens new GMP manufacturing facility
- Seeking Alpha
- Loading more headlines...